As labs implement TMB workflows in-house, studies are showing that its is possible to validate assays with cutoff points remaining stable across complex clinical cohorts and in different drug contexts.
The researchers aimed to develop a test that could help clinicians determine whether a patient would respond to therapy, before the onset of treatment.
A proteogenomic analysis by a Moffitt Cancer Center-led team uncovered three subtypes of squamous cell lung cancer and treatment approaches to investigate.
Progression-free survival times were comparable for EGFR-mutated non-small cell lung cancer cases treated with a combination of erlotinib and bevacizumab treatment or erlotinib.
Chi Van Dang discussed major breakthroughs now moving out into community practice, continued challenges, and promising new areas oncologists may want to watch.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
